Strategic Combinations

WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) and AbCellera (Nasdaq: ABCL) this week announced a multi-year, multi-program partnership to discover, develop, and commercialize potentially first-in-class treatments for patients with …